Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 14Neoplasms 10Thoracic Neoplasms 3Carcinoma 3Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2NSCLC 2Meningeal Carcinomatosis 2Lung Diseases 2Colorectal Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Solid Tumor, Adult 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Lethal Congenital Contracture Syndrome 2 1Hemangioendothelioma, Epithelioid 1Head and Neck Neoplasms 1

Interventions

tetulomab tetraxetan lu-177 2osimertinib 2fludarabine 2entinostat 2Pemetrexed 2Lutetium 2Carboplatin 2spartalizumab 1pembrolizumab 1nirogacestat 1interferon gamma-1b 1gilteritinib 1ficlatuzumab 1emvododstat 1denileukin diftitox 1atezolizumab 1Trabectedin 1Taxes 1Sunitinib 1Radiosurgery 1Oncolytic Virotherapy 1Nivolumab 1Lutetium-177 1Interleukin-2 1Interferon-gamma 1Immunotherapy 1Idarubicin 1HuMax-IL8 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms by Histologic Type × osimertinib × Clear all
NCT04862780 2025-02-10

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
177 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05153408 2023-06-18

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
20 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡